Get the Stockscreener App
2.115
7.07%
-0.165
Jasper Therapeutics Inc stock is traded at $2.115, with a volume of 242.88K.
It is down -7.07% in the last 24 hours and down -14.91% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$2.28
Open:
$2.26
24h Volume:
242.88K
Relative Volume:
0.76
Market Cap:
$34.46M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-0.3419
EPS:
-6.1852
Net Cash Flow:
$-52.33M
1W Performance:
-9.07%
1M Performance:
-14.91%
6M Performance:
-60.84%
1Y Performance:
-90.04%
1-Day Range:
$2.05
$2.2644
1-Week Range:
$2.05
$2.52
52-Week Range:
$2.05
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
2.1199 | 63.67M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.76 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.33 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.40 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.30 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.16 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-07-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-13-25 | Initiated | UBS | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead - GlobeNewswire
Jasper Therapeutics Inc expected to post a loss of $1.21 a shareEarnings Preview - TradingView
JSPR DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors ... - Bluefield Daily Telegraph
JSPR DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – JSPR - GlobeNewswire Inc.
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Jasper Therapeutics, Inc. (JSPR), Quanex Building Products Corporation (NX), and RCI Hospitality Holdings, Inc. (RICK) - GlobeNewswire
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JSPR Deadline: JSPR Investors with Losses in Excess of $100K Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Sahm
JSPR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In JSPR To Contact Him Directly To Discuss Their Options - Lelezard
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain OfficersJSPR - Lelezard
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
Boston Herald - FinancialContent
Jasper Therapeutics’ Briquilimab Study: Long-Term Safety and Market Implications - TipRanks
Jasper Therapeutics Advances Briquilimab Study for Chronic Urticaria - TipRanks
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
JSPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsJSPR - Lelezard
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire
Is Jasper Therapeutics Inc Equity Warrant a good long term investmentMarket Rumors and News & Minimal Investment Trading Tips - earlytimes.in
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Jasper Therapeutics ... - Bluefield Daily Telegraph
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Lelezard
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers – JSPR - FinancialContent
JSPR Stockholders Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JASPER CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Jasper Therapeutics ... - Black Hills Pioneer
What analysts say about Jasper Therapeutics Inc Equity Warrant stockMarket Profile Overview & Budget Friendly Trading Alerts - earlytimes.in
Can Jasper Therapeutics Inc. stock weather global recessionMonthly Report 2025 & Develop Consistency in Trading Habits - nchmf.gov.vn
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
JSPR Shareholders Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JSPR Investors Should Contact Robbins LLP Regarding the - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FinancialContent
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JASPER CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
What analysts say about Jasper Therapeutics Inc stockEconomic Indicators Overview & Explore Stocks for Free with Our Research Portal - earlytimes.in
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) - GlobeNewswire
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JSPR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - Stockhouse
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):